Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain

NCT ID: NCT02899884

Last Updated: 2019-11-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3765 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-14

Study Completion Date

2018-07-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an unselected, representative cohort of cancer outpatients with or without pain who attend consultations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study has been designed as a non-interventional, non post-authorization, cross-sectional, epidemiological study to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an non-selected, representative cohort of cancer outpatients with or without pain.

The study enrolled 3765 patients. This multicenter trial will be conducted in Spain. Data from participants will be collected through questionnaire and medical history in a single visit (up to 1 month).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breakthrough Cancer Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.

No Intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants≥ 18 years old
* Participants with baseline cancer pain that is adequately controlled with opioids
* Presence of episodes of breakthrough pain associated with the cancer pain
* Meeting the diagnostic criteria for breakthrough cancer pain (participant history and Portenoy's criteria) and the Davies algorithm
* Participants who are not receiving treatment for breakthrough cancer pain. It is not permitted the inclusion of participants receiving treatment for breakthrough cancer pain in order to avoid bias that may affect the characterization or taxonomy of breakthrough cancer pain
* Signing of the informed consent

Exclusion Criteria

* Severe mental illness
* Any medical condition or situation complicating the collection of study data as determined by the investigator
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Takeda

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital General Universitario de Elda-Virgen de La Salud

Elda, Alicante, Spain

Site Status

Hospital Universitario San Juan de Alicante

San Juan, Alicante, Spain

Site Status

Hospital Universitari Son Espases

Palma de Mallorca, Balearic Islands, Spain

Site Status

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, Spain

Site Status

Hospital Universitari Germans Trias I Pujol de Badalona

Badalona, Barcelona, Spain

Site Status

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital de Especialidades de Puerto Real

Puerto Real, Cadiz, Spain

Site Status

Hospital Universitario de Gran Canaria Dr. Negrin

Las Palmas de Gran Canaria, Canary Islands, Spain

Site Status

Complejo Hospitalario Universitario Insular-Materno Infantil

Las Palmas de Gran Canarias, Canary Islands, Spain

Site Status

Hospital Universitario Nuestra Senora de Candelaria

Santa Cruz de Tenerife, Canary Islands, Spain

Site Status

Hospital de Alta Resolucion de Guadix

Guadix, Granada, Spain

Site Status

Hospital Universitario Principe de Asturias

Alcalá de Henares, Madrid, Spain

Site Status

Hospital Universitario Puerta de Hierro, Majadahonda

Majadahonda, Madrid, Spain

Site Status

Hospital Quiron Madrid

Pozuelo de Alarcón, Madrid, Spain

Site Status

Complejo Hospital Costa Del Sol

Marbella, Malaga, Spain

Site Status

Hospital General Universitario Santa Lucia

Cartagena, Murcia, Spain

Site Status

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital Los Montalvos

Carrascal de Barregas, Salamanca, Spain

Site Status

Complexo Hospitalario Universitario A Coruna

A Coruña, , Spain

Site Status

Centro Oncoloxico de Galicia

A Coruña, , Spain

Site Status

Hospital Torrecardenas

Almería, , Spain

Site Status

Hospital Puerta Del Mar

Cadiz, , Spain

Site Status

Hospital Reina Sofia

Córdoba, , Spain

Site Status

Hospital Universitario Virgen de Las Nieves

Granada, , Spain

Site Status

Complejo Hospitalario de Jaen

Jaén, , Spain

Site Status

Hospital Universitario de La Princesa

Madrid, , Spain

Site Status

Hospital Universitario Fundacion Jimenez Diaz

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Complejo Hospitalario Regional de Malaga

Málaga, , Spain

Site Status

Hospital Virgen de La Victoria

Málaga, , Spain

Site Status

Hospital Universitario de Salamanca

Salamanca, , Spain

Site Status

Hospital Nuestra Senora de Valme

Seville, , Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Hospital Universitario Doctor Peset

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CARPEDIO Study

Identifier Type: OTHER

Identifier Source: secondary_id

Fentanyl-5001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.